AstraZeneca will soon start a phase 3 trial of a subcutaneous version of its anti-CD19 T-cell engager.
ApexOnco Front Page
Recent articles
A son of glembatumumab vedotin has just started its phase 1 study.
No fewer than four ADCs with this target start human testing.
On a cross-trial basis varegacestat beats Ogsiveo.
Lilly reveals that an Inluriyo/Verzenio combo is being limited to ESR1-mutant disease.
The group will start a pivotal trial of samuraciclib following promising second-line results.
Some time ago Opdivo beat Adcetris in an NCI trial, and now Bristol files.
Arcus steps back from TIGIT as its Fc-silent claim crumbles.
